Search Bar & Filters
Found 2 Actively Recruiting clinical trials
Actively Recruiting
Researchers are evaluating whether accelerated BEP chemotherapy is more effective than standard BEP chemotherapy for males aged 11 to 50 years with intermediate and poor-risk metastatic germ cell tumors. This Phase 3 trial aims to improve cure rates for these patients since previous attempts to enhance first-line chemotherapy have been unsuccessful and more toxic. The study is sponsored by the University of Sydney and compares two chemotherapy schedules in this patient population. Participants receive either standard or accelerated BEP chemotherapy. The standard treatment involves 4 cycles every 3 weeks including bleomycin, etoposide, cisplatin, and supportive drugs like pegylated G-CSF or filgrastim, with treatment lasting about 12 weeks. The accelerated arm administers cycles every 2 weeks with similar drugs and doses but includes additional bleomycin after the 4 cycles. Dosages vary based on age and weight, and treatment is personalized by the physician. During the study, participants undergo regular assessments including response evaluations at the end of chemotherapy and at 6 months, safety monitoring for adverse events, and quality of life questionnaires up to 18 months. Researchers measure progression-free survival and overall survival for up to 5 years. The trial involves randomized assignment to treatment groups and careful monitoring of chemotherapy dosing and patient health throughout the study period.
Actively Recruiting
Researchers are evaluating the efficacy and safety of Datopotamab Deruxtecan Dato-DXd combined with Rilvegostomig, or Rilvegostomig alone, compared with Pembrolizumab alone as first-line treatments for people with locally advanced or metastatic non-squamous non-small cell lung cancer NSCLC. Participants must have high PD-L1 expression tumor cells 50% and no actionable genomic mutations. This is a Phase III, randomized, open-label global study focusing on these treatments for this specific lung cancer type. Participants will be assigned to one of three groups one receiving Dato-DXd plus Rilvegostomig, another receiving Rilvegostomig alone, and a third receiving Pembrolizumab alone. All treatments are given by intravenous infusion every three weeks on Day 1 of each 21-day cycle. The study will monitor participants over several years to compare these therapies as first-line options. During the study, participants will undergo regular assessments including imaging and tumor sampling to measure progression-free survival and overall survival, focusing on those with TROP2 biomarker positivity. Other evaluations include response rates, duration of response, lung cancer symptoms, quality of life, physical functioning, pharmacokinetics, and immunogenicity over approximately 4 to 6 years. Safety monitoring and long-term follow-up are part of the participant involvement.